Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IX 4976	SERIAL NO. 09/995,529
	APPLICANT: Watkins et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 11/26/01	GROUP: 1632 / 1642 SR

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
SR		5,223,409	6/29/93	Ladner et al.	435	69.7	3/1/91
		5,264,563	11/23/93	Huse	536	25.3	12/14/92
		5,403,484	4/4/95	Ladner et al.	435	235.1	1/26/93
		5,523,388	6/4/96	Huse	536	22.1	2/27/95
		5,871,974	2/16/99	Huse	435	69.7	12/2/94

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)
SR		WO 98/33919	06/08/98	PCT			
		WO 99/06834	11/02/99	PCT			
		WO 00/40597	13/07/00	PCT			
		WO 00/78815	28/12/02	PCT			
		WO 01/27160	19/04/01	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

SR		Chothia and Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins," J. Mol. Biol., 196:901-917 (1987).
		Glaser et al., "Antibody Engineering by Condon-Based Mutagenesis in a Filamentous Phage Vector System," J. Immunology, 149(12):3903-3913 (1992).

EXAMINER	DATE CONSIDERED
	4/21/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IX 4976	SERIAL NO. 09/995,529
	APPLICANT: Watkins et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 11/26/01	GROUP: 1632

SR		Huse et al., "Application of a Filamentous Phage pVIII Fusion Protein System Suitable for Efficient Production, Screening, and Mutagenesis of F(ab) Antibody Fragments," J. Immunology, 149(12):3914--3920 (1992).
		Kabat et al., "Unusual Distributions of Amino Acids in Complemetarity-determining (Hypervariable) Segments of Heavy and Light Chains of Immunoglobulins and Their Possible Roles in Specificity of Antibody-combining Sites," J. Biol. Chem., 252(19):6609-6616 (1977).
		Kabat et al., "Sequences of Proteins of Immunological Interest," U.S. Department of Health and Human Services (1991)
		Kristensson et al., "Humanization of a Murine Antibody against Cryptococcus neoformans Polysaccharide Using a Novel Approach,"in Vaccines 95, pp.39-43 Cold Spring Harbor Laboratory, Cold Spring Harbor (1995).
		Kunkel, "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," Proc. Natl. Acad. Sci. USA, 82(2):488-492 (1985).
		MacCallum et al., "Antibody-antigen interactions: contact analysis and binding site topography" J. Mol. Biol., 262:732-745 (1996).
		Watkins et al., "Determination of the Relative Affinities of Antibody Fragments Expressed in Escherichia coli by Enzyme-Linked Immunosorbent Assay," Analytical Biochem., 253:37-45 (1997).
		Wu et al., "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues," J. Mol. Biol., 294:151-162 (1999).
		Wu et al., "Stepwise in vitro affinity maturation of Vitaxin, an $\alpha_v\beta_3$-specific humanized mAb," Proc. Natl. Acad. Sci. USA., 95:6037-6042 (1998).

EXAMINER	DATE CONSIDERED
J Rawlings	4/21/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1449.pat

Form PTO 1449	US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-IX 4976	SERIAL NO. 09/995,529
		APPLICANT: Watkins et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: 11/26/01	GROUP: 1632

SR		Xu et al., "Generation of Monoclonal Antibodies to Cryptic Collagen Sites by Using Subtractive Immunization," Hybridoma, 19(5): 375-385 (2000).
↓		Xu et al., "Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo," J. Cell Biol., 154(5):1069-1079 (2001).

EXAMINER	DATE CONSIDERED
[signature]	4/21/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1449.pat